| Market Cap | 5.45M | P/E | - | EPS this Y | 67.10% | Ern Qtrly Grth | - |
| Income | -17.46M | Forward P/E | -0.69 | EPS next Y | 47.00% | 50D Avg Chg | -23.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
| Dividend | N/A | Price/Book | 0.52 | EPS next 5Y | - | 52W High Chg | -79.00% |
| Recommedations | 2.00 | Quick Ratio | 1.07 | Shares Outstanding | 7.29M | 52W Low Chg | 102.00% |
| Insider Own | 7.06% | ROA | -86.20% | Shares Float | 7.17M | Beta | 0.58 |
| Inst Own | 6.71% | ROE | -197.47% | Shares Shorted/Prior | 254.87K/95.06K | Price | 2.62 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,625,088 | Target Price | 8.00 |
| Oper. Margin | - | Earnings Date | May 13 | Volume | 33,973 | Change | -1.50% |
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
| HC Wainwright & Co. | Buy | Jan 30, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PASQUALONE FRANK | Director Director | Sep 15 | Buy | 2.14 | 1,000 | 2,140 | 1,000 | 09/19/23 |